Delving into the Latest Updates on Pregabalin with Synapse

Overview

Basic Info

SummaryPregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions. Such conditions include but are not limited to anxiety disorders, epilepsy, and neuralgia. The mechanism of action that characterizes pregabalin's utility involves blocking the CACNA2D1 and CACNA2D2 calcium channels, thus effectively targeting these disorders with aplomb. The Upjohn Co. received approval for the medical use of pregabalin in the European Union as far back as 2004, indicating that the medication has been a key feature of medical treatment for some time. Pregabalin's indications primarily target the treatment of neuropathic pain conditions, including fibromyalgia, and partial onset seizures in combination with other anticonvulsant medications. These conditions are managed with pregabalin due to its efficacy in minimizing their attendant symptoms. Pregabalin, therefore, serves as a vital tool in the management of chronic pain and neurological disorders.

Drug Type

Small molecule drug

Synonyms

LYRICA CR

+ [10]

Target

CACNA2D1 x CACNA2D2

Mechanism

CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication

FibromyalgiaSeizuresNeuralgia, Postherpetic+ [7]

Inactive Indication

Acute herpes zoster neuropathyBreast CancerComplex Regional Pain Syndromes+ [30]

Originator Organization

The Upjohn Co.

Active Organization

Huizhi Pharmaceutical (Dalian) Co., Ltd.

Pfizer Inc.Upjohn EESV

+ [14]

Inactive Organization

Viatris, Inc.MyLan SAS

John Hunter Hospital

+ [6]

Drug Highest PhaseApproved

First Approval Date

EU (05 Jul 2004),

Epilepsies, PartialEpilepsyGeneralized anxiety disorder+ [1]

RegulationSpecial Review Project (CN), Priority Review (CN)

Login to view timeline

Structure/Sequence

Molecular FormulaC8H17NO2

InChIKeyAYXYPKUFHZROOJ-ZETCQYMHSA-N

CAS Registry148553-50-8

The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy.
The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC).
This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks.
Participants will:
* Undergo a quantitative sensory testing (QST) exam.
* Provide a blood sample.
* Complete questionnaires on the computer.
* Take the study drug as instructed.

Start Date01 Sep 2025

Sponsor / Collaborator

University of Rochester

[+1]

ACTRN12624001359527

/ Not yet recruitingPhase 3IIT

A Phase III double-blind placebo-controlled randomised controlled trial to evaluate effectiveness of early treatment with pregabalin in the development of chronic pain in adults with acute whiplash injury

Start Date24 Feb 2025

Sponsor / Collaborator

The University of Queensland

NCT06150898

/ Not yet recruitingPhase 2IIT

Unravelling the Local and Systemic Effects of Primary Surgery and Perioperative Use of Ketorolac and Pregabalin in Primary Breast Cancer Patients According to Adiposity

Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer.
To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug.
Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs

Start Date01 Jan 2025

Sponsor / Collaborator

Jules Bordet Institute

[+1]

100 Clinical Results associated with Pregabalin

Login to view more data

100 Translational Medicine associated with Pregabalin

Login to view more data

100 Patents (Medical) associated with Pregabalin

Login to view more data

4,751

Literatures (Medical) associated with Pregabalin

01 Feb 2025·Pain

Pregabalin is associated with a higher overdose risk but the risk with gabapentin is not negligible

Article

Author: Hamina, Aleksi ; Skurtveit, Svetlana ; McDonald, Rebecca

01 Feb 2025·Journal of Ethnopharmacology

Qisheng wan decoction alleviates the inflammation of CCI rats via TRP channels

Article

Author: Xiang, Chunxiao ; Li, Zaiqi ; Wei, Guihua ; Wang, Haoyan ; Yan, Zhiyong ; Wu, Yating ; Li, Xi

ETHNOPHARMACOLOGICAL RELEVANCEQisheng wan decoction (QWD), a traditional Chinese medicine, has promising potential anti-inflammatory effects against neuropathic pain (NP). However, its valid ingredients and specific anti-inflammatory mechanisms are still unclear.AIM OF THE STUDYThis study aimed to identify the active ingredients of QWD responsible for its anti-inflammatory effect by combining liquid chromatography with network pharmacology, and to explore its anti-inflammatory mechanism by chronic constriction injury (CCI) model rats.MATERIALS AND METHODSThe UHPLC-Q Exactive Orbitrap-MS technique was used to identify the active ingredients of QWD. The potential ingredients of QWD, which targeted to the pathways of treating NP, were performed by network pharmacology, molecular docking and molecular dynamics simulations. After CCI rats-induced NP model operation, QWD (5.6 g/kg/d, 11.2 g/kg/d, 22.4 g/kg/d) and Pregabalin (10 g/kg/d) as positive controls, were administered to the rats for 7 days. The behaviors of the different groups were tested at 0, 1, 3, 5, 7, 12 days, respectively. And the inflammatory factor including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) was detected by ELISA. Meantime, the inflammation of the sciatic nerve was evaluated by the hematoxylin-eosin staining. Ionized calcium-binding adapter molecule-1 (Iba-1) and glial fibrillary acidic protein (GFAP) were detected by immunohistochemistry. Moreover, the expressions of TRPA1, TRPV1, TRPV2, TRPV3, TRPV4, TRPM8, and P38 mitogen-activated protein kinase (MAPK) were tested by RT-PCR, Western blot, and immunohistochemistry.RESULTSAfter screening by the liquid chromatography and network pharmacology approach, seventy ingredients of QWD were identified, and seven core targets including oncogene tyrosine-protein kinase (SRC), mitogen-activated protein kinase 3 (MAPK3), signal transducer and activator of transcription 1 (STAT1), protein-serine-threonine kinase 1 (AKT1), mitogen-activated protein kinase 1 (MAPK1), TNF-α, and IL-6 were confirmed. Six active ingredients exhibited binding energies less than -5 kcal/mol, and the complexes were structurally stable within 50 ns. Pathway analysis indicated that transient receptor potential (TRP) channels were mainly responsible for anti-inflammatory mediator regulation. Compared with the CCI group, the behavioral tests showed that QWD-L, QWD-M, and QWD-H group alleviated mechanical, thermal and cold hyperalgesia (p < 0.05). HE staining results found out QWD-L, QWD-M, and QWD-H group decreased the inflammation of the sciatic nerve (p < 0.05). Similarly, compared with the CCI group, the serum level of TNF-α and IL-6 of QWD groups decreased conformably (p < 0.05). This reduction was downtrend with the inhibition of Iba-1, GFAP, and the TRP channel signaling pathway and p38 MAPK.CONCLUSIONSThis study provides a primary investigation of the composition of QWD for its anti-inflammation effect and its molecular mechanism in CCI model rats. And this therapeutic efficacy of QWD was achieved by decreasing the inflammation. QWD also inhibited the level TNF-α and IL-6 and decreasing the activation of Iba-1 and GFAP in glia. And this anti-inflammation mechanism involved in inhibiting the TRPA1, TRPV1, TRPV2, TRPV4, and TRPM8 and p38 MAPK signaling pathways. These findings provide a scientific and theoretical basis for the prevention and treatment of NP with QWD.

01 Feb 2025·Radiology Case Reports

Early neurological deterioration with severe headache as the initial manifestation: A case report

Article

Author: Tao, Meichun ; Yang, Yaping ; Cheng, Hao ; Dong, Mei

Severe headache as the initial clinical manifestation of early neurological deterioration (END) is uncommon. The emergence of severe headache should be promptly recognized as a potential indicator of large vessel stenosis. Here, we describe a male patient who initially presented with severe headache accompanied by transient left limb weakness, which subsequently progressed to persistent weakness. Imaging studies revealed severe stenosis at the origin of the right internal carotid artery, along with the presence of asymmetrically prominent cortical veins (APCV). Despite the administration of pregabalin orally and tramadol intramuscularly, his headache persisted. However, significant alleviation of his headache symptoms was observed following the improvement of cerebral perfusion. Re-examination revealed the resolution of cortical vein dilation. This case underscores the importance of recognizing severe headache and APCV as potential indicators of large vessel stenosis and early neurological deterioration (END). Improving cerebral perfusion may serve as an effective means of alleviating headache symptoms in such cases.

68

News (Medical) associated with Pregabalin

19 Dec 2024

·www.accesswire.com

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ketamir-2, its novel oral ketamine analog for the treatment of neuropathic pain. The IND submission marks a major step in advancing Mira's lead drug candidate while reflecting its commitment to meeting milestones and timelines.Erez Aminov, Chairman & CEO of Mira, stated: "This IND submission highlights our team's commitment to executing efficiently as we advance transformative therapies. Ketamir-2 not only has demonstrated remarkable potential for neuropathic pain but also offers a broad opportunity across other major neuropsychiatric conditions. We look forward to beginning Phase I trials and continuing to deliver on our mission to address unmet medical needs."The IND application includes comprehensive data and reports detailing Ketamir-2's pharmacology, pharmacokinetics, and toxicology, along with results from both in vitro and in vivo studies, including validated neuropathic pain disease models. In parallel with the submission, the company is preparing to conduct a complementary neurotoxicity study, as required by the FDA's written feedback to the pre-IND documentation.According to a market analysis report from Fortune Business Insights, the neuropathic pain market in North America, including the United States, Canada, and Mexico, is valued at $3.1 billion and is expected to grow at a 6-7% compound annual growth rate (CAGR), reaching $4.5 billion by 2030. Despite this growth, existing treatments remain inadequate. Gabapentin and pregabalin, while widely prescribed, provide limited efficacy and are associated with side effects such as sedation, dizziness, and weight gain. Opioids remain a common treatment option but come with well-known risks of dependency, addiction, and respiratory depression. Intravenous ketamine, though effective for some patients, requires invasive administration and is often associated with psychotropic side effects, including hallucinations and dissociation.Ketamir-2 is specifically designed to address the limitations of existing treatments through its selective targeting of the NMDA receptor. By binding to a specific site on the NMDA receptor with low affinity, Ketamir-2 significantly reduces the risk of psychotropic effects commonly associated with traditional ketamine. Furthermore, it is not a substrate for P-glycoprotein (P-gp), which allows for better oral absorption and enhanced blood-brain barrier penetration. Unlike traditional ketamine, Ketamir-2 does not cause sedation or hyperactivity-side effects often linked to psychiatric conditions such as schizophrenia, bipolar mania, and ADHD. As a non-opioid therapy, Ketamir-2 is designed to eliminate the risks of dependency and addiction. Additionally, the DEA has determined that Ketamir-2 is not a controlled substance, streamlining accessibility and minimizing regulatory hurdles.Preclinical studies have demonstrated Ketamir-2's ability to achieve 100% pain reversal, fully normalizing pain thresholds in validated neuropathic pain models. Furthermore, Ketamir-2 has shown a strong safety and toxicological profile, observed across cardiovascular, CNS, respiratory, or toxicology assessments.Dr. Itzchak Angel, Chief Scientific Advisor at Mira, commented: "Ketamir-2's selective mechanism of action, strong safety profile, and ability to achieve full pain reversal underscore its potential as a transformative therapy."With the IND submitted, MIRA expects to initiate Phase I Clinical Trials in Q1 2025 to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers. Phase IIa trials are expected to follow in late 2025 to assess efficacy in neuropathic pain patients. Beyond neuropathic pain, the company is exploring additional indications for Ketamir-2, including MDD, MDD-SI, TRD and PTSD.About MIRA Pharmaceuticals, Inc.MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.The U.S. Drug Enforcement Administration's scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.Additional information about MIRA Pharmaceuticals is available at www.mirapharmaceuticals.com.Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.Contact InformationHelga Moya [email protected](786) 432-9792SOURCE: Mira Pharmaceuticals, Inc.

Phase 1Phase 2IND

02 Dec 2024

·www.drugs.com

Guidelines Developed for Treatment of Restless Legs Syndrome

MONDAY, Dec. 2, 2024 -- In a clinical practice guideline issued by the American Academy of Sleep Medicine and published online Sept. 26 in the Journal of Clinical Sleep Medicine , recommendations are presented for the treatment of restless legs syndrome (RLS). John W. Winkelman, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues developed recommendations for treatment of RLS and periodic limb movement disorder in adults and pediatric patients. The researchers developed three good practice statements that were based on expert consensus. They recommend all clinicians should regularly test serum iron studies, including ferritin and transferrin saturation, in all patients with clinically significant RLS, ideally in the morning; analysis of these studies influences the decision to use oral or intravenous (IV) iron treatment. The authors also state that addressing exacerbating factors, including alcohol, caffeine, antihistaminergic, serotonergic, and anti-dopaminergic medications, should be the first step in RLS management. They note RLS is common in pregnancy and the pregnancy-specific safety profile of each treatment should be considered. Recommendations for adults with RLS include use of gabapentin enacarbil over no gabapentin enacarbil; use of gabapentin over no gabapentin; use of pregabalin over no pregabalin; and use of IV ferric carboxymaltose over no IV ferric carboxymaltose for those with appropriate iron status (strong recommendations; moderate certainty of evidence). In addition, there is a strong recommendation against use of cabergoline. "Guided by the best evidence in the scientific literature, we've provided recommendations that will improve the ability of clinicians to provide patient-centered care for people who have RLS," Winkelman said in a statement. One author disclosed ties to the pharmaceutical and medical device industries. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

29 Nov 2024

·www.globenewswire.com

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data Expected in Q1 2025 Nov. 26, 2024 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of patient enrollment in the PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) study evaluating LX9211, a novel, orally-delivered, selective investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1), for the treatment of diabetic peripheral neuropathic pain (DPNP). The study successfully enrolled 494 patients, approximately 20 percent more than originally targeted, marking a significant milestone in the trial and increasing study power. Top-line data from PROGRESS is expected to be announced in Q1 2025. "We are pleased to have completed enrollment for the PROGRESS study of LX9211 in DPNP, a condition for which there is significant need for new, non-opioid treatment options," said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. "The strong interest in this study resulted in enrollment significantly exceeding the target and completion of enrollment eight weeks ahead of schedule, underscoring the urgent demand in DPNP. We are confident that the greater-than-expected enrolled patient population will lead to critical insights, inform our Phase 3 design and add to the body of evidence supporting the use of LX911 in treating neuropathic pain and we look forward to sharing top-line findings from the study early next year." PROGRESS commenced in December of 2023 with the goal of enrolling adult patients with a diagnosis of diabetes (type 1 or type 2) with moderate to severe DPNP. The study is placebo-controlled with a primary endpoint of reduction of Average Daily Pain Score (ADPS) at 8 weeks. Secondary endpoints include change from baseline in burning pain and pain interference with sleep. Study design permitted patients to maintain one stable-dose DPNP therapy (gabapentin, pregabalin or duloxetine) without being forced to withdraw from therapies that, although inadequate, may be providing benefit – aligning with how new DPNP drugs are likely to be used in practice. DPNP is a type of nerve damage caused by chronically high blood sugar and is a major disabling and devastating consequence of long-term diabetes. It can result in pain, numbness, and other symptoms in the hands, feet, legs, and arms. There are approximately 20 million patients in the U.S. who are suffering with some type of neuropathic pain, of which about 5 million have DPNP. Discovered using Lexicon’s unique approach to gene science, LX9211 is a potent, orally delivered, selective, investigational small molecule inhibitor of AAK1. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain. Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. LX9211 received Fast Track designation from the U.S. Food and Drug Administration for development in DPNP. Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com. The content above comes from the network. if any infringement, please contact us to modify.

Fast TrackClinical Result

100 Deals associated with Pregabalin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02716	Pregabalin	N03AX16	DB00230

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Fibromyalgia	US	Upjohn US 2 LLC	21 Jun 2007
Seizures	AU	Viatris Pty Ltd.	13 Apr 2005
Neuralgia, Postherpetic	US	CP Pharmaceuticals Ltd.	30 Dec 2004
Epilepsies, Partial	NO	Upjohn EESV	05 Jul 2004
Epilepsies, Partial	IS	Upjohn EESV	05 Jul 2004
Epilepsies, Partial	EU	Upjohn EESV	05 Jul 2004
Epilepsies, Partial	LI	Upjohn EESV	05 Jul 2004
Epilepsy	IS	Upjohn EESV	05 Jul 2004
Epilepsy	LI	Upjohn EESV	05 Jul 2004
Epilepsy	EU	Upjohn EESV	05 Jul 2004
Epilepsy	NO	Upjohn EESV	05 Jul 2004
Generalized anxiety disorder	LI	Upjohn EESV	05 Jul 2004
Generalized anxiety disorder	IS	Upjohn EESV	05 Jul 2004
Generalized anxiety disorder	EU	Upjohn EESV	05 Jul 2004
Generalized anxiety disorder	NO	Upjohn EESV	05 Jul 2004
Neuralgia	LI	Upjohn EESV	05 Jul 2004
Neuralgia	NO	Upjohn EESV	05 Jul 2004
Neuralgia	IS	Upjohn EESV	05 Jul 2004
Neuralgia	EU	Upjohn EESV	05 Jul 2004

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	Phase 3	LI	MyLan SAS	25 Jun 2015
Epilepsy	Phase 3	LI	MyLan SAS	25 Jun 2015
Epilepsy	Phase 3	EU	MyLan SAS	25 Jun 2015
Epilepsy	Phase 3	EU	MyLan SAS	25 Jun 2015
Diabetic peripheral neuropathy	Discovery	US	Pfizer Inc.	30 Dec 2004
Neuralgia, Postherpetic	Discovery	US	Pfizer Inc.	30 Dec 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04122196 (CTgov)	Phase 2/3	Kidney Calculi \| Pain, Postoperative	118	Pregabalin 300mg (Pregabalin 300mg)	dbulyzzcev(ytvpqfntlf) = mzqvlsmcmv ghgyszaxgi (btodkcifmc, hgyjarrats - ckjtapzzac) View more	-	24 Oct 2024
				Placebo oral tablet (Placebo)	dbulyzzcev(ytvpqfntlf) = ichkqcsfph ghgyszaxgi (btodkcifmc, qrmugcjpqv - dkgleenrgx) View more
NCT04015908 (CTgov)	Phase 4	-	100	Pregabalin+Acetaminophen+Celecoxib+Oxycodone (Multi-modal)	kscqfqikei(zjobxdusmg) = scrbqvoaxp qgfaqxwtyn (ilbihvgbiz, qavlaaodpw - okptptwxet) View more	-	08 Jul 2024
				Percocet (Control)	kscqfqikei(zjobxdusmg) = yqjqzkevln qgfaqxwtyn (ilbihvgbiz, hfuuegtnme - awnvmjxgjl) View more
NCT04218240 (PGB-LOF, CTgov)	Phase 2	Opioid abuse	90	Pregabalin 200 MG capsules+Lofexidine 0.18Mg Tab (PGB/LFX;)	lgagsnzooe(wymwpsecqr) = gsdbcvsjxg funxicxrki (dwlfeufnpz, eoiqeqquwh - noufetssia) View more	-	20 May 2024
				Placebo oral tablet+Lofexidine 0.18Mg Tab (Lofexidine and PLACEBO)	lgagsnzooe(wymwpsecqr) = zlpxouxezo funxicxrki (dwlfeufnpz, zlxwkipzgk - abedksnjrn) View more
NCT02884908 (CTgov)	Phase 3	Alcohol Use Disorder \| Stress Disorders, Post-Traumatic	57	BBCET+Pregabalin (Pregabalin + BBCET)	fdgwscigvc(uiqhqzydnh) = yagzczzkkh gzwygcvoif (bhosojyrtp, pgqoqdfhex - vrxyecyuhb) View more	-	13 Mar 2024
				Placebo (Placebo + BBCET)	fdgwscigvc(uiqhqzydnh) = axdrmeriuk gzwygcvoif (bhosojyrtp, washakuomd - sccugvcnir) View more
ESMO_ASIA2023	Not Applicable	Add-on	84	Olanzapine 5 mg plus pregabalin 75 mg	imwnmgovob(mdjasbylka) = xnsnptragy zfonuyiboz (alcjwdndho )	-	02 Dec 2023
				Placebo	imwnmgovob(mdjasbylka) = zaxczlxszk zfonuyiboz (alcjwdndho )
NCT00310765 (CTgov)	Phase 4	Abdominal Pain \| Tissue Adhesions \| Surgical Adhesion	18	pregabalin+placebo (Patients Treated With Placebo)	mjgfbjecud(jvnjjobvdm) = yitpbgffjh huuuhzrgqj (tkqyiulbgm, jzajspdgas - tibkbrmqig) View more	-	23 Oct 2023
				Pregabalin (Patients Treated With Pregabalin)	mjgfbjecud(jvnjjobvdm) = jszvujuxcx huuuhzrgqj (tkqyiulbgm, plcovynkqz - dpoypicwcb) View more
NCT04246619 (BLOSSOM, Pubmed)	Phase 4	Diabetic peripheral neuropathic pain	254	Pregabalin	(vjhiogpfic) = wmemkmoghy szirpaddsh (sffgitpjhl, [ - 41.4, to 32.6]) View more	Positive	18 Jul 2023
				Duloxetine	(vjhiogpfic) = alkfhsgihr szirpaddsh (sffgitpjhl, [ - 41.5, to 32.3]) View more
EULAR2023	Not Applicable	Cancer Pain	-	Pregabalin	wrxayksqdv(nkqsjunlhx) = rnrwnogkcf soljdgsvvx (uwdadoekoq )	Negative	31 May 2023
				Gabapentin	wrxayksqdv(nkqsjunlhx) = mnwxdthcad soljdgsvvx (uwdadoekoq )
NCT01801189 (CTgov)	Phase 4	Pain, Postoperative	61	pregabalin (Pregabalin)	lhpwcfxvsa(kbmpmophlu) = cfmijwgaxy iofjwgdbvb (xhqzbiiwcr, ekardofvlh - hbfrdngtly) View more	-	06 Jun 2022
				Placebo (for Pregabalin) (Sugar Pill)	lhpwcfxvsa(kbmpmophlu) = tjowgueehw iofjwgdbvb (xhqzbiiwcr, tnisgxkllo - ncscauyvhl) View more
NCT01271660 (Pubmed \| Eur Spine J \| J Korean Med Sci) Manual	Phase 3	Liver Cirrhosis \| Muscle Cramp	56	pregabalin	rnbuybmtpm(txdneuzanq) = ordznqpapa zrghoycjnu (gxrakpdisl )	Positive	21 Feb 2022
				Placebo	rnbuybmtpm(txdneuzanq) = kvgfonjytb zrghoycjnu (gxrakpdisl )